Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Lymphoma × TQ-B3525 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uterine Cervical Neoplasms 1 Sarcoma, Ewing 1 Recurrence 1 Ovarian Neoplasms 1 Osteosarcoma 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma 1 HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer 1 Chondrosarcoma 1

Interventions

Cyclophosphamide 33 Vincristine 23 Etoposide 21 Cytarabine 19 Radiotherapy 17 Doxorubicin 17 Rituximab 16 Melphalan 16 Peripheral Blood Stem Cell Transplantation 14 Prednisolone 13 Filgrastim 13 Methotrexate 12 fludarabine phosphate 11 Prednisone 11 Dexamethasone 9 Carmustine 9 Bleomycin 9 Cyclosporine 8 Busulfan 8 Ifosfamide 7 Cisplatin 7 Vinblastine 6 Gemcitabine 6 Antilymphocyte Serum 6 sargramostim 5 pegylated granulocyte colony-stimulating factor 5 fludarabine 5 Mitoxantrone 5 Methylprednisolone 5 Chlorambucil 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03510767 2023-04-14

A Study of TQ-B3525 on Tolerance and Pharmacokinetics

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Unknown

Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡